SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.260
+0.045 (1.40%)
Sep 29, 2026, 2:30 PM EDT - Market open
SAB Biotherapeutics Employees
SAB Biotherapeutics had 86 employees as of December 31, 2025. The number of employees increased by 23 or 36.51% compared to the previous year.
Employees
86
Change (1Y)
23
Growth (1Y)
36.51%
Revenue / Employee
n/a
Profits / Employee
-$253,346
Market Cap
296.62M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 86 | 23 | 36.51% |
| Dec 31, 2024 | 63 | 6 | 10.53% |
| Dec 31, 2023 | 57 | 1 | 1.79% |
| Dec 31, 2022 | 56 | -83 | -59.71% |
| Mar 31, 2022 | 148 | 62 | 72.09% |
| Dec 31, 2021 | 139 | 53 | 61.63% |
| Sep 30, 2021 | 143 | 57 | 66.28% |
| Jun 30, 2021 | 137 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Abeona Therapeutics | 226 |
| EyePoint | 214 |
| Rocket Pharmaceuticals | 202 |
| BridgeBio Oncology Therapeutics | 88 |
| Century Therapeutics | 78 |
| Upstream Bio | 75 |
| X4 Pharmaceuticals | 45 |
SABS News
- 7 days ago - SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes - GlobeNewsWire
- 19 days ago - SAB Biotherapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 4 weeks ago - SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - SAB Biotherapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 7 weeks ago - SAB Biotherapeutics Earnings release: Q2 2026 - Filings
- 7 weeks ago - SAB Biotherapeutics Quarterly report: Q2 2026 - Filings
- 7 weeks ago - SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - GlobeNewsWire
- 2 months ago - SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET - GlobeNewsWire